Teng Lin, Qin Qin, Zhou Zi-Yi, Zhou Fei, Cao Cun-Yu, He Chao, Ding Jia-Wang, Yang Jian
Department of Cardiology, Yichang Central People's Hospital, NO, 183 Yiling Road, Yichang, 443003, Hubei, People's Republic of China.
School of Cardiovascular and Metabolic Medicine & Sciences, King's College London British Heart Foundation Centre of Research Excellence, London, SE5 9NU, UK.
Biochem Genet. 2025 Feb;63(1):832-849. doi: 10.1007/s10528-024-10713-9. Epub 2024 Mar 25.
The study aims to explore the fluctuating expression of C/EBP Homologous Protein (CHOP) following rat carotid artery injury and its central role in vascular stenosis. Using in vivo rat carotid artery injury models and in vitro ischemia and hypoxia cell models employing human aortic endothelial cells (HAECs) and vascular smooth muscle cells (T/G HA-VSMCs), a comprehensive investigative framework was established. Histological analysis confirmed intimal hyperplasia in rat models. CHOP expression in vascular tissues was assessed using Western blot and immunohistochemical staining, and its presence in HAECs and T/G HA-VSMCs was determined through RT-PCR and Western blot. The study evaluated HAEC apoptosis, inflammatory cytokine secretion, cell proliferation, and T/G HA-VSMCs migration through Western blot, ELISA, CCK8, and Transwell migration assays. The rat carotid artery injury model revealed substantial fibrous plaque formation and vascular stenosis, resulting in an increased intimal area and plaque-to-lumen area ratio. Notably, CHOP is markedly elevated in vessels of the carotid artery injury model compared to normal vessels. Atorvastatin effectively mitigated vascular stenosis and suppresses CHOP protein expression. In HAECs, ischemia and hypoxia-induced CHOP upregulation, along with heightened TNFα, IL-6, caspase3, and caspase8 levels, while reducing cell proliferation. Atorvastatin demonstrated a dose-dependent suppression of CHOP expression in HAECs. Downregulation of CHOP or atorvastatin treatment led to reduced IL-6 and TNFα secretion, coupled with augmented cell proliferation. Similarly, ischemia and hypoxia conditions increased CHOP expression in T/G HA-VSMCs, which was concentration-dependently inhibited by atorvastatin. Furthermore, significantly increased MMP-9 and MMP-2 concentrations in the cell culture supernatant correlated with enhanced T/G HA-VSMCs migration. However, interventions targeting CHOP downregulation and atorvastatin usage curtailed MMP-9 and MMP-2 secretion and suppressed cell migration. In conclusion, CHOP plays a crucial role in endothelial injury, proliferation, and VSMCs migration during carotid artery injury, serving as a pivotal regulator in post-injury fibrous plaque formation and vascular remodeling. Statins emerge as protectors of endothelial cells, restraining VSMCs migration by modulating CHOP expression.
本研究旨在探讨大鼠颈动脉损伤后C/EBP同源蛋白(CHOP)的表达变化及其在血管狭窄中的核心作用。利用体内大鼠颈动脉损伤模型以及采用人主动脉内皮细胞(HAECs)和血管平滑肌细胞(T/G HA-VSMCs)的体外缺血缺氧细胞模型,建立了一个全面的研究框架。组织学分析证实大鼠模型中存在内膜增生。通过蛋白质免疫印迹法和免疫组织化学染色评估血管组织中CHOP的表达,并通过逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹法确定其在HAECs和T/G HA-VSMCs中的存在情况。本研究通过蛋白质免疫印迹法、酶联免疫吸附测定(ELISA)、细胞计数试剂盒8(CCK8)和Transwell迁移试验评估HAEC凋亡、炎性细胞因子分泌、细胞增殖以及T/G HA-VSMCs迁移情况。大鼠颈动脉损伤模型显示有大量纤维斑块形成和血管狭窄,导致内膜面积和斑块与管腔面积比增加。值得注意的是,与正常血管相比,颈动脉损伤模型血管中的CHOP明显升高。阿托伐他汀有效减轻血管狭窄并抑制CHOP蛋白表达。在HAECs中,缺血缺氧诱导CHOP上调,同时肿瘤坏死因子α(TNFα)、白细胞介素6(IL-6)、半胱天冬酶3(caspase3)和半胱天冬酶8(caspase8)水平升高,而细胞增殖减少。阿托伐他汀在HAECs中呈剂量依赖性抑制CHOP表达。CHOP下调或阿托伐他汀治疗导致IL-6和TNFα分泌减少,同时细胞增殖增加。同样,缺血缺氧条件下T/G HA-VSMCs中CHOP表达增加,阿托伐他汀可浓度依赖性抑制该表达。此外,细胞培养上清液中基质金属蛋白酶9(MMP-9)和基质金属蛋白酶2(MMP-2)浓度显著增加与T/G HA-VSMCs迁移增强相关。然而,针对CHOP下调的干预措施和使用阿托伐他汀可减少MMP-9和MMP-2分泌并抑制细胞迁移。总之,CHOP在颈动脉损伤期间的内皮损伤、增殖以及VSMCs迁移中起关键作用,是损伤后纤维斑块形成和血管重塑的关键调节因子。他汀类药物作为内皮细胞的保护剂,通过调节CHOP表达来抑制VSMCs迁移。